Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP).
about
Molecular Tweezers Targeting Transthyretin AmyloidosisTransthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor.Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide--relevance in Alzheimer's disease.Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants.Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val30Met.Altered protein folding may be the molecular basis of most cases of cystic fibrosis.Transthyretin Induces Insulin-like Growth Factor I Nuclear Translocation Regulating Its Levels in the HippocampusEvidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55ProAnalysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathyA New Folding Kinetic Mechanism for Human Transthyretin and the Influence of the Amyloidogenic V30M Mutation.Transthyretin participates in beta-amyloid transport from the brain to the liver--involvement of the low-density lipoprotein receptor-related protein 1?Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis.Resveratrol administration increases Transthyretin protein levels ameliorating AD features - importance of transthyretin tetrameric stability.Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design.Clusterin overexpression and its possible protective role in transthyretin deposition in familial amyloidotic polyneuropathy.αB-crystallin (HspB5) in familial amyloidotic polyneuropathy.Transthyretin binding to A-Beta peptide--impact on A-Beta fibrillogenesis and toxicity.Familial amyloid polyneuropathy.Structure of Met30 variant of transthyretin and its amyloidogenic implications.4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid.Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation.Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor.Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.Designing transthyretin mutants affecting tetrameric structure: implications in amyloidogenicity.Insulin amyloid fibrillation at above 100 degrees C: new insights into protein folding under extreme temperatures.MMP-14 overexpression correlates with the neurodegenerative process in familial amyloidotic polyneuropathy.Aprotinin binding to amyloid fibrils.The V30M Amyloidogenic Mutation Decreases the Rate of Refolding Kinetics of the Tetrameric Protein TransthyretinTetramer Dissociation and Monomer Partial Unfolding Precedes Protofibril Formation in Amyloidogenic Transthyretin VariantsThe Tetrameric Protein Transthyretin Dissociates to a Non-native Monomer in SolutionThe amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution
P2860
Q29030065-BCF358C2-0DBA-45DB-8F08-43046106A8E2Q33358106-C85CB60C-9EED-456A-A01B-B0E02832250EQ34428889-51884E4A-74A3-4184-8723-1A9D7D6CA962Q35066532-3A4620DD-9358-4A2C-8614-FF8F2D7B1CB5Q35083244-5DC6BF5A-880F-4AD6-BAE6-74B2AFC186C0Q35344873-EE9C02F2-2361-4311-9A4D-F64E01A07765Q35616785-D0AF59E0-5CB1-494D-88BC-C37B535922F4Q35747781-074405F4-D956-481F-B508-D42AFBC753F9Q35764345-9C580FEC-D596-4D5A-9F9B-9C3FF6BE91C9Q36121846-66F80D35-7F94-44E2-BDA0-95785AACB40CQ36536181-227ADF73-C9AB-4683-B631-D91F55A2C0DEQ36919063-A80504C2-46D7-4B47-B52D-EC89591819D8Q37370545-2C731C90-6480-4D29-8086-3C3B5C7E48F2Q39254356-E7198331-2120-46A3-A652-6D4C59FD4879Q39443274-5523C349-B126-4569-8F75-7D5679DD02FAQ39661743-96536F40-B61C-4538-A1C6-F229156EC5F8Q40009615-19CE983F-7684-4020-81FA-E7B045D10587Q40807251-893E83A1-4A57-4F73-91FE-3A17FF6F3BF9Q40872049-AFC5D899-E333-4227-973A-FBA000DFA17FQ42048697-ED71E2CE-F4B2-468F-BD6E-05EC2E9141DBQ42050715-0BACCF7B-231B-4A5A-8537-209F3AB993AEQ42096099-DE3C840F-3BD5-4ECF-8A99-BC41CEC152B1Q42806704-50BAF59E-50E0-4A5C-95DE-E423596E5960Q42996641-22E47B6F-C9DE-4507-BB3E-6AE413669A8AQ43095166-F90AEA65-650B-4776-8177-E36A674AFB85Q45913428-EC69CF19-2080-4F1C-BA75-537F5BADDDBBQ46305215-5CE6128E-24C4-414B-8FA1-8C1997345D57Q57665540-E1A00237-BCF4-4AAD-B892-B6B997AAAC95Q57665571-C81FD448-ACBC-401C-A8ED-C1F0A007DEA6Q57665576-A575AE29-6D2E-4081-984F-759AA4FD3BAFQ57665578-628895D7-977B-41DA-958D-07BF7F4E3791
P2860
Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP).
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Production of recombinant huma ...... loidotic polyneuropathy (FAP).
@en
type
label
Production of recombinant huma ...... loidotic polyneuropathy (FAP).
@en
prefLabel
Production of recombinant huma ...... loidotic polyneuropathy (FAP).
@en
P2093
P356
P1433
P1476
Production of recombinant huma ...... yloidotic polyneuropathy (FAP)
@en
P2093
M A Gawinowicz
P304
P356
10.1021/BI00223A017
P407
P577
1991-03-01T00:00:00Z